CurrentBlue Cross Blue Shield - MassachusettsPolicy 291

Intravenous Infusion of Anesthetics (Ketamine, Lidocaine) for Chronic Pain — Coverage Criteria

This policy governs coverage of IV anesthetic infusions (e.g., ketamine, lidocaine) for treatment of chronic pain syndromes across commercial and Medicare product lines, states the payer position (investigational or not covered) and authorization requirements.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyIntravenous Infusion of Anesthetics (Ketamine, Lidocaine) for Chronic Pain — Coverage Criteria

Policy CodePolicy 291

Change TypeAnnual review — no material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

INVESTIGATIONALpolicy stance

Not coveredoutpatient coverage

Precert requiredinpatient auth

291policy id

RCTs & reviewsevidence types

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Policy Stance

Investigational / Not Covered

Covered when ALL of the following are met:

Investigational statement: Intravenous infusion of anesthetics (eg, ketamine or lidocaine) for the treatment of chronic pain, including, but not limited to chronic neuropathic pain, chronic daily headache, and fibromyalgia, is INVESTIGATIONAL.

Applies to Commercial and Medicare products as specified.

This policy applies to outpatient and inpatient settings, but for outpatient services it specifies that intravenous anesthetic infusions described herein are not a covered service for the listed product lines. The products called out include Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, and Medicare HMO and PPO, where outpatient administration of IV anesthetics is explicitly identified as not covered.

The policy’s reference sections list clinical studies and reviews relevant to IV anesthetic infusions but do not add additional, explicit coverage exclusions beyond those stated in the policy body.

Available evidence, including systematic reviews, randomized trials, and observational studies, is limited and inconsistent: trials of IV lidocaine have not shown durable benefit, and small ketamine trials show only short-term relief with methodological concerns. Given limited durability of effect and safety concerns, the evidence is insufficient to demonstrate improvement in net health outcome for IV anesthetic infusions for chronic pain.

Although the document cites multiple references, those citation lists do not themselves include explicit statements declaring IV anesthetic infusions to be 'not medically necessary'; the policy text conveys the evidence-based stance rather than additional not-medically-necessary declarations in the reference sections.

Billing and Code Listings

HCPCS Codes (investigational per policy)HCPCSNot Covered

J2002	Injection, lidocaine hcl in 5% dextrose, 1 mg.
J2003	Injection, lidocaine hydrochloride, 1 mg.
J2004	Injection, lidocaine hcl with epinephrine, 1 mg

Provider Requirements, Authorization, and Billing Guidance

Prior Authorization

Precertification Required

Precertification/preauthorization is required for ALL inpatient services described in this policy. Failure to obtain required precertification may result in denial or reduced payment.

Applies to all products when procedure is performed inpatient.

Note

No authorization statements are present

For outpatient services, no prior authorization statements are specified in the referenced outpatient sections of this policy. Providers should check member-specific benefit plans for any product-level outpatient authorization requirements.

The policy text lists outpatient services as not covered for several product types, but does not specify prior authorization processes in the referenced sections.

Conservative Treatment and Prior Therapies

Frequency and Treatment Limits

intravenous ketamine or lidocaine infusions — frequency limits

Frequency limit summaryNo specific numeric frequency limit or time period is specified in the policy for intravenous ketamine or lidocaine infusions; the policy lists these procedures under frequency_limits but provides no quantitative limits.

Procedure namesIntravenous ketamine infusion; Intravenous lidocaine infusion.

ApplicabilityApplies to treatment of chronic pain syndromes (eg, chronic neuropathic pain, chronic daily headache, fibromyalgia) as addressed in the policy.

Documentation implicationBecause no frequency limits are defined, provider requests for repeated infusions should reference clinical rationale and cited literature; outpatient infusions are not covered for many products (see coverage statements).

Imaging and Diagnostic Requirements

Note

No imaging requirements specified

No imaging requirements are specified in the referenced sections of this policy.

Background and Clinical Context

Intravenous lidocaine and ketamine have been investigated as treatments for chronic neuropathic pain, chronic daily headache including migraine, and fibromyalgia. Studies include systematic reviews, randomized controlled trials, and observational reports. Reported benefits are limited in magnitude and duration and must be weighed against significant adverse event profiles for these agents (for example, cardiac and neurologic risks with lidocaine and dissociative and respiratory risks with ketamine). Overall, current clinical evidence raises concerns about long-term efficacy and safety of repeat courses, supporting a cautious approach to their use for chronic pain.

Definitions and Clinical Terms

Chronic daily headache — definition and criteria

DefinitionChronic daily headache: a headache disorder that occurs 15 or more days a month for more than 3 months; includes chronic migraine, new daily persistent headache, hemicranias continua, and chronic tension-type headache.

Common included disordersChronic migraine; new daily persistent headache; hemicranias continua; chronic tension-type headache.

Relevance to policyIV anesthetic infusions (eg, ketamine, lidocaine) have been reported for chronic headache and are considered in the policy context for chronic daily headache.

Neuropathic pain — definition and clinical features

DefinitionNeuropathic pain: pain often disproportionate to the primary triggering injury, which may include allodynia, dysesthesia, and/or hyperalgesia; symptoms may persist ≥6 months and involve peripheral and central sensitization.

Explicit Not Covered Services

Outpatient intravenous infusion of anesthetics (eg, lidocaine, ketamine) for chronic pain is listed as not a covered service for specified Commercial and Medicare product lines. Because the evidence does not demonstrate durable net benefit and safety concerns persist, these outpatient infusions are considered investigational and will be denied when billed under the referenced products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyIntravenous Infusion of Anesthetics (Ketamine, Lidocaine) for Chronic Pain — Coverage Criteria

Policy CodePolicy 291

Change TypeAnnual review — no material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient.

SourceLink

On This Page

Documentation Required

No documentation requirements specified

There are no additional documentation requirements specified in the referenced sections of this policy. Standard medical record documentation and coding practices apply.

Providers should report services using current procedure, revenue, and diagnosis codes and include modifiers where applicable (informational).

Step Therapy

Step Therapy Context (informational)

Step-therapy context (informational): The policy discusses use of IV infusions both as test infusions to assess responsiveness and as part of broader treatment programs for conditions such as neuropathic pain and fibromyalgia; however, the policy does not establish step-therapy pathways or mandatory trials of other therapies prior to infusions.

Test infusions have been used in treatment planning to assess responsiveness to subsequent oral agents (eg, mexiletine or ketamine).
A course of IV lidocaine or ketamine at subanesthetic doses has been examined in some contexts, distinct from continuous infusions for terminal cancer pain.

Note

No step therapy requirements specified

No step therapy requirements are specified in the referenced sections of this policy. Providers should follow clinical judgment and any applicable member benefit rules.

The policy does not mandate prior trials or step-up medication sequences before considering infusions; check member-specific benefits for programmatic requirements.

Allodynia (pain from normally nonpainful stimuli), dysesthesia (ongoing unpleasant/electrical pain sensation), hyperalgesia (exaggerated response to painful stimuli).

Pathophysiology and treatment contextThought to result from peripheral afferent sensitization and central nervous system reorganization; treatments focus on reducing activity and desensitizing pain pathways (NMDA receptor–mediated); test anesthetic infusions have been used to assess responsiveness to agents like mexiletine or ketamine.

Fibromyalgia — definition and clinical features

DefinitionFibromyalgia: a chronic state of widespread pain and tenderness, considered a disorder of central pain processing (central sensitization) with focal tender points and biochemical alterations.

Biochemical and clinical featuresAlterations in NMDA receptors, low serotonin, suppressed dopamine release in limbic system, hypothalamic-pituitary-adrenal dysfunction, and elevated substance P; focal hyperalgesia at muscle-tendon junctions (tender points).

Typical treatmentsTypically treated with neuropathic pain medications (eg, pregabalin), non-narcotic analgesics, or low-dose antidepressants; IV anesthetic infusions have been investigated but are not supported by evidence for chronic pain in this policy.

Consensus guidelines — professional society guidance summaries

Key consensus guidelineConsensus Guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists provide guidance on use of intravenous ketamine infusions for chronic pain (Reg Anesth Pain Med. Jul 2018).

Mood disorders guidanceA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders (JAMA Psychiatry. Apr 2017) informs practice for psychiatric indications and is cited in the policy references.

Scope of cited guidanceGuidelines and consensus statements cited address both chronic pain and psychiatric uses of ketamine and are used to inform clinical practice considerations in the policy.